Cargando…
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, sy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235874/ https://www.ncbi.nlm.nih.gov/pubmed/34194882 http://dx.doi.org/10.7759/cureus.15280 |
_version_ | 1783714419117654016 |
---|---|
author | Phan, Alexander T Gukasyan, Janet Arabian, Sarkis Wang, Sharon Neeki, Michael M |
author_facet | Phan, Alexander T Gukasyan, Janet Arabian, Sarkis Wang, Sharon Neeki, Michael M |
author_sort | Phan, Alexander T |
collection | PubMed |
description | Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications. |
format | Online Article Text |
id | pubmed-8235874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-82358742021-06-29 Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia Phan, Alexander T Gukasyan, Janet Arabian, Sarkis Wang, Sharon Neeki, Michael M Cureus Internal Medicine Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications. Cureus 2021-05-27 /pmc/articles/PMC8235874/ /pubmed/34194882 http://dx.doi.org/10.7759/cureus.15280 Text en Copyright © 2021, Phan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Phan, Alexander T Gukasyan, Janet Arabian, Sarkis Wang, Sharon Neeki, Michael M Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title | Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title_full | Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title_fullStr | Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title_full_unstemmed | Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title_short | Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia |
title_sort | emergent inpatient administration of casirivimab and imdevimab antibody cocktail for the treatment of covid-19 pneumonia |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235874/ https://www.ncbi.nlm.nih.gov/pubmed/34194882 http://dx.doi.org/10.7759/cureus.15280 |
work_keys_str_mv | AT phanalexandert emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia AT gukasyanjanet emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia AT arabiansarkis emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia AT wangsharon emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia AT neekimichaelm emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia |